CACI vs NVDA

CACI exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating robust operational efficiency. While the current price of $516.54 is significantly above the defensive Graham Number ($313.75), it trades at a substantial discount to its growth-based intrinsic value of $688.83 and analyst targets. Despite bearish short-term technicals and insider selling, the company's consistent track record of earnings beats and double-digit EPS growth support a long-term bullish outlook.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.